Samantha Prout's most recent trade in Amicus Therapeutics Inc was a trade of 12,240 Common Stock done at an average price of $14.3 . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 12,240 | 125,951 (0%) | 0% | 14.3 | 174,665 | Common Stock |
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 3,443 | 138,191 (0%) | 0% | 14.3 | 49,132 | Common Stock |
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 32,193 | 141,634 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 27,416 | 122,941 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.57 per share. | 11 Feb 2025 | 13,500 | 109,441 (0%) | 0% | 9.6 | 129,195 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,715 | 62,715 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 34,614 | 105,097 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 8,275 | 96,822 (0%) | 0% | 9.4 | 77,868 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 3,443 | 70,483 (0%) | 0% | 9.3 | 32,054 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 1,297 | 95,525 (0%) | 0% | 9.4 | 12,205 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.66 per share. | 15 Apr 2024 | 7,027 | 73,926 (0%) | 0% | 10.7 | 74,908 | Common Stock |
| Amicus Therapeutics Inc | Prout Samantha | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 08 Jan 2024 | 30,767 | 82,290 (0%) | 0% | 14.0 | 430,827 | Common Stock |
| Amicus Therapeutics Inc | Prout Samantha | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 08 Jan 2024 | 1,337 | 80,953 (0%) | 0% | 14 | 18,718 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.53 per share. | 03 Jan 2024 | 8,142 | 114,353 (0%) | 0% | 13.5 | 110,161 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.44 per share. | 03 Jan 2024 | 1,296 | 113,057 (0%) | 0% | 13.4 | 17,418 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 43,592 | 43,592 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 25,252 | 123,808 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.19 per share. | 31 Dec 2023 | 23,356 | 98,556 (0%) | 0% | 14.2 | 331,422 | Common Stock |
| Amicus Therapeutics Inc | Prout Samantha | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.24 per share. | 31 Dec 2023 | 1,313 | 122,495 (0%) | 0% | 14.2 | 18,697 | Common Stock |
| Amicus Therapeutics Inc | Prout Samantha | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 26 Dec 2023 | 7,659 | 121,912 (0%) | 0% | 14.0 | 107,228 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.77 per share. | 17 Aug 2023 | 7,432 | 129,571 (0%) | 0% | 12.8 | 94,907 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 14.01 per share. | 09 Aug 2023 | 36,909 | 137,003 (0%) | 0% | 14.0 | 516,933 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 18,901 | 37,810 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.11 per share. | 09 Aug 2023 | 18,901 | 173,912 (0%) | 0% | 12.1 | 228,891 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 10,592 | 3,176 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 09 Aug 2023 | 10,592 | 155,011 (0%) | 0% | 10.0 | 106,238 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 5,040 | 2,526 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.55 per share. | 09 Aug 2023 | 5,040 | 144,419 (0%) | 0% | 9.6 | 48,132 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 2,376 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.04 per share. | 09 Aug 2023 | 2,376 | 139,379 (0%) | 0% | 10.0 | 23,855 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 03 Sep 2021 | 4,925 | 83,170 (0%) | 0% | 12.0 | 59,168 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.55 per share. | 03 Sep 2021 | 2,945 | 88,095 (0%) | 0% | 9.6 | 28,125 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 2,945 | 12,182 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2021 | 1,980 | 3,168 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.04 per share. | 03 Sep 2021 | 1,980 | 85,150 (0%) | 0% | 10.0 | 19,879 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 23 Aug 2021 | 5,045 | 83,170 (0%) | 0% | 11 | 55,495 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 24,201 | 88,875 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.33 per share. | 15 Apr 2021 | 660 | 88,215 (0%) | 0% | 10.3 | 6,818 | Common Stock |